Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CTI BioPharma stock

Own CTI BioPharma stock in just a few minutes.

CTI BioPharma Corp is a biotechnology business based in the US. CTI BioPharma shares (CTIC) are listed on the NASDAQ and all prices are listed in US Dollars. CTI BioPharma employs 22 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in CTI BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTIC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CTI BioPharma share price

Use our graph to track the performance of CTIC stocks over time.

CTI BioPharma shares at a glance

Information last updated 2021-04-30.
52-week range$0.96 - $4.03
50-day moving average $2.74
200-day moving average $3.20
Wall St. target price$7.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.62

Buy CTI BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CTI BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CTI BioPharma financials

Gross profit TTM $3.3 million
Return on assets TTM -52.11%
Return on equity TTM -180.99%
Profit margin 0%
Book value $0.53
Market capitalisation $227.1 million

TTM: trailing 12 months

Shorting CTI BioPharma shares

There are currently 1.7 million CTI BioPharma shares held short by investors – that's known as CTI BioPharma's "short interest". This figure is 413.9% up from 334,322 last month.

There are a few different ways that this level of interest in shorting CTI BioPharma shares can be evaluated.

CTI BioPharma's "short interest ratio" (SIR)

CTI BioPharma's "short interest ratio" (SIR) is the quantity of CTI BioPharma shares currently shorted divided by the average quantity of CTI BioPharma shares traded daily (recently around 1.7 million). CTI BioPharma's SIR currently stands at 1.04. In other words for every 100,000 CTI BioPharma shares traded daily on the market, roughly 1040 shares are currently held short.

However CTI BioPharma's short interest can also be evaluated against the total number of CTI BioPharma shares, or, against the total number of tradable CTI BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CTI BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CTI BioPharma shares in existence, roughly 20 shares are currently held short) or 0.0225% of the tradable shares (for every 100,000 tradable CTI BioPharma shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CTI BioPharma.

Find out more about how you can short CTI BioPharma stock.

CTI BioPharma share dividends

We're not expecting CTI BioPharma to pay a dividend over the next 12 months.

Have CTI BioPharma's shares ever split?

CTI BioPharma's shares were split on a 1:10 basis on 2 January 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CTI BioPharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for CTI BioPharma shares which in turn could have impacted CTI BioPharma's share price.

CTI BioPharma share price volatility

Over the last 12 months, CTI BioPharma's shares have ranged in value from as little as $0.9629 up to $4.03. A popular way to gauge a stock's volatility is its "beta".

CTIC.US volatility(beta: 0.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CTI BioPharma's is 0.8125. This would suggest that CTI BioPharma's shares are less volatile than average (for this exchange).

CTI BioPharma overview

CTI BioPharma Corp. , a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. ; S*BIO Pte Ltd. ; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site